Faggiano P, D'Aloia A, Dei Cas L
Cattedra di Cardiologia, Università degli Studi di Brescia.
Monaldi Arch Chest Dis. 2002 May;58(1):47-50.
A simple blood test useful to the diagnosis and follow-up of congestive heart failure would have a favorable impact on the management of a large populations of patients. Several recent studies have demonstrated that blood levels of Brain Natriuretic Peptide (BNP) may be useful for differentiating heart failure from lung disease in patients presenting to emergency department with dyspnea. Furthermore, BNP might serve as screening test for left ventricular dysfunction (systolic and diastolic), correlates with severity of congestive heart failure and is an independent predictor of outcome. Finally, BNP changes correlate with variations of hemodynamic profile induced by therapy and can be used for a noninvasive tailoring of treatment. These findings make this peptide a potential "white count" for patients with suspected or confirmed heart failure.
一种有助于充血性心力衰竭诊断及随访的简单血液检测，将对大量患者的管理产生积极影响。最近的几项研究表明，对于因呼吸困难前往急诊科就诊的患者，脑钠肽（BNP）的血液水平可能有助于区分心力衰竭与肺部疾病。此外，BNP可用作左心室功能障碍（收缩和舒张功能）的筛查测试，与充血性心力衰竭的严重程度相关，并且是预后的独立预测指标。最后，BNP的变化与治疗引起的血流动力学变化相关，可用于无创调整治疗方案。这些发现使这种肽成为疑似或确诊心力衰竭患者的潜在“白细胞计数指标”。
